Former Komen grantee and lead investigator on the EMERALD Clinical Trial Dr. Aditya Bardia explains the treatment gap that the EMERALD clinical trial sought to fill for people with metastatic estrogen receptor-positive breast cancer. The results of this clinical trial led to the approval of elacestrant, or Orserdu.
Kelsey Hampton, PhD, is Senior Manager, Mission Communications at Susan G. Komen
Dr. Aditya Bardia is a medical oncologist at Massachusetts General Hospital
Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: [ Ссылка ]
Link to Survey: [ Ссылка ]
Clinical Trial Finder: [ Ссылка ]
Videos:
Breast Cancer Breakthroughs Episode 7: Brining Treatments to Life: [ Ссылка ]
Under the Microscope: Mutations: [ Ссылка ]
Under the Microscope: Estrogen Receptor: [ Ссылка ]
Resources:
Metastatic Breast Cancer: [ Ссылка ]
Hormone Receptor Status: [ Ссылка ]
Hormone therapy for metastatic breast cancer: [ Ссылка ]
Monitoring metastatic breast cancer: [ Ссылка ]
Emerging areas in diagnosis: [ Ссылка ]
Emerging areas in metastatic breast cancer treatment: [ Ссылка ]
EMERALD Trial (Active, not recruiting): [ Ссылка ]
